Your session is about to expire
← Back to Search
Pembrolizumab for Melanoma
Study Summary
This trial is testing a new drug, GR-MD-02, in combination with the standard dose of pembrolizumab, in patients with advanced melanoma, non-small cell lung cancer, or head and neck squamous cell cancer.
- Melanoma
- Non-Small Cell Lung Cancer
- Squamous Cell Carcinoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are new participants being taken for this research project?
"At this time, the trial is not seeking out patients. Originally posted on May 16th 2016 and most recently updated July 13th 2022, it appears to have paused recruitment for now. If you are considering other options, there are 5030 studies currently recruiting melanoma sufferers as well as 962 trials looking for Pembrolizumab participants."
What are the most common indications of Pembrolizumab treatment?
"Pembrolizumab is often employed to combat malignant neoplasms, however it can also be beneficial in cases of unresectable melanoma, microsatellite instability high levels and disease progression after chemotherapy."
Are there any other investigations involving Pembrolizumab that have yielded results?
"Currently, there are 962 ongoing clinical trials exploring the effects of Pembrolizumab with 123 in Phase 3. Numerous locations across 35876 sites have been carrying out these trials; one such region is Houston, Texas."
What is the upper bound of participants in this experiment?
"Unfortunately, this trial is not currently accepting new participants. Originally posted on May 16th 2016 and last amended July 13th 2022, the study has reached its recruitment target. Patients seeking other medical trials may want to explore the 5030 melanoma studies and 962 Pembrolizumab inquiries which are still open for enrolment."
Has the U.S Food and Drug Administration sanctioned Pembrolizumab for therapeutic usage?
"The safety of Pembrolizumab is estimated to be a 1 due to the limited data available from Phase 1 trials. This suggests that there is minimal evidence backing its efficacy and security."
Share this study with friends
Copy Link
Messenger